SRPT
Sarepta Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$20.11
−2.71%Price chart
Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18
Key dataSep 18, 2026
Open$20.63
From 52W high−17.75%
Volume6.25M
Market cap$2.12B
P/E (TTM)—
P/S (TTM)1.1x
Div yield—
Key dataSep 18, 2026
Open
$20.63
From 52W high
−17.75%
Volume
6.25M
Market cap
$2.12B
ValuationView details →
P/E (Fwd)
35.0x
EV/EBITDA
−163.3x
P/E (TTM)
—
RSI (14)
49.6
MomentumView details →
1D Return
−2.71%
YTD Return
−7.16%
SummaryUpdated Jun 1, 2026
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) is a commercial-stage biopharmaceutical company founded in 1980 and headquartered in Cambridge, Massachusetts. The company went public in 1997 and has evolved from a research-focused organization into a leading developer of RNA-targeted therapeutics and gene therapies for rare neuromuscular diseases. Sarepta achieved a major milestone in 2023 with the FDA approval of ELEVIDYS, the first gene therapy for Duchenne muscular dystrophy, transforming the company from a loss-making biotech into a profitable enterprise with over $1.9 billion in annual revenue as of 2024.
Similar companies
Latest newsMore news →
Shares of Dyne Therapeutics and Sarepta Therapeutics fell on Tuesday after Novartis' muscle disease drug failed a trial, raising investor concerns about similar therapies.12d agoSarepta Therapeutics shares rose 12% on Thursday, rebounding from July lows, as investors looked ahead to upcoming clinical data.24d ago